Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide

Jon Mabley, Jignesh Patel, Abdelrahman Sayed, Roopen Arya, Greg Scutt

Research output: Contribution to journalLetterpeer-review


Anticoagulant therapy is commonly prescribed for both the acute treatment, and long-term prevention of venous thromboembolism (VTE), and as primary and secondary prevention of stroke in the context of atrial fibrillation (AF) [1]. Until recently the majority of patients requiring chronic anticoagulant therapy were prescribed vitamin K antagonists (VKA), as these were the only oral anticoagulant agents available [1]. A requirement for regular monitoring and VKA-drug or-food interactions has meant that not all patients that have an indication for anticoagulation have benefitted from these agents.
Original languageEnglish
Pages (from-to)36-38
Number of pages3
JournalThrombosis Research
Publication statusPublished - 12 Feb 2019


  • Apixaban
  • Endothelial
  • Factor Xa inhibitors
  • Nitric oxide
  • Rivaroxaban
  • Vasodilation


Dive into the research topics of 'Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide'. Together they form a unique fingerprint.

Cite this